Allen Melemed compensation by year
CHIMERIX Summary Compensation Table · all 2 fiscal years held| Component | FY2022 | FY2023 |
|---|---|---|
| Salary | $465,150 | $488,408 |
| Bonus | $0 | $0 |
| Stock awards | $0 | $50,708 |
| Option awards | $866,823 | $215,588 |
| Non-equity incentive | $130,242 | $166,059 |
| Pension and deferred compensation | $0 | $0 |
| All other | $9,901 | $11,031 |
| Total | $1,472,116 | $931,794 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: CHIMERIX INC DEF 14A filed April 26, 2024, accession 0001117480-24-000010, and prior-year filings.
How this page was built: the CHIMERIX INC filed document, accession 0001117480-24-000010. Every figure is read from that document and cited to the page and table it appears in. Filed April 26, 2024.
Equity holdings
unvested awards at FY2023 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 25,740 | $24,775 | — |
| Option | 50,000 | — | $3.11 |
| Option | 51,459 | — | $9.28 |
| Option | 125,000 | — | $5.62 |
| Option | 118,909 | — | $1.97 |
Per the Outstanding Equity Awards at Fiscal Year-End table in CHIMERIX INC's FY2023 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
10 Form 4 lines since the FY2023 proxy (filed April 26, 2024)current to 2026-11-07 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2025-04-21 | Disposition to the issuer derivative | — | 400,000 | — | 0 |
| 2025-04-21 | Disposition to the issuer | — | 173,852 | $8.55 | 0 |
| 2025-04-21 | Disposition to the issuer derivative | — | 240,000 | — | 0 |
| 2025-04-21 | Disposition to the issuer derivative | — | 275,000 | — | 0 |
| 2025-04-21 | Disposition to the issuer derivative | — | 190,000 | — | 0 |
| 2025-04-21 | Disposition to the issuer derivative | — | 154,260 | — | 0 |
| 2025-04-21 | Disposition to the issuer derivative | — | 168,750 | — | 0 |
| 2025-02-13 | Sale | — | 3,065 | $4.50 | 152,875 |
The 8 most recent of 10 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
CHIMERIX’s named executive officers, FY2023
as the company reported each| Named executive officer | Role | FY2023 total |
|---|---|---|
| Mike Sherman | Former President and Chief Executive Officer | $1,517,854 |
| Mike Andriole | President and Chief Executive Officer | $1,312,421 |
| Allen Melemed · this page | Chief Medical Officer | $931,794 |
| Michael Alrutz | Senior Vice President, General Counsel and Corporate Secretary | $793,854 |
The full CHIMERIX compensation record
free company briefThis page is one person within CHIMERIX's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the CHIMERIX proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are CHIMERIX's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.